# US 2022/0008520 A1 · Methods and materials for reducing age-related striated muscle and cognitive decline

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0008520 A1
- Document ID: US20220008520A1
- Status: Published application
- Kind: A1
- Application number: 17/294,726
- Filed: 2019-11-21
- Published: 2022-01-13
- Earliest claimed: 2018-11-21
- Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education
- Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education
- Inventors: Fabrisia Ambrosio; Aaron Barchowsky; Amin Cheikhi; Rada Koldamova; Iliya Lefterov; Amrita Sahu
- Web page: https://patentgrep.com/patent/US20220008520A1

## CPC

- A61K 38/47: acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- C12N 9/2402: {hydrolysing O- and S- glycosyl compounds (3.2.1)}
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 38/19: Cytokines; Lymphokines; Interferons
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61P 21/06: Anabolic agents (androgens A61P5/26)
- C07K 14/71: for growth factors; for growth regulators
- C12Y 302/01031: Beta-glucuronidase (3.2.1.31)
- C12Y 302/02: hydrolysing N-glycosyl compounds (3.2.2)
- A01K 2217/077: heterozygous knock out animals displaying phenotype
- A01K 2227/105: Murine
- A01K 2267/035: Animal model for multifactorial diseases
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS

## Abstract

This document provides methods and materials for treating aging. For example, a mammal having, or at risk for developing, an age-related impairment (e.g., age-related cognitive decline) can be treated by increasing the level of one or more myokine polypeptides (e.g., one or more Klotho polypeptides) within cells within the mammal. This document also provides methods and materials for increasing the ability of muscle progenitor cells to regenerate muscle cells by increasing the level(s) of one or more myokine polypeptides (e.g., an α-Klotho polypeptide) within a muscle progenitor cell.

## Claims

### Claim 1

A method for reducing sarcopenia or age-related cognitive decline within a mammal, wherein said method comprises administering exosomes comprising an α-Klotho polypeptide or a nucleic acid encoding said α-Klotho polypeptide to said mammal.

### Claim 2 (depends on 1)

The method of claim 1, wherein said mammal is a human.

### Claim 3 (depends on 1)

The method of claim 1, wherein said method comprises administering exosomes comprising said α-Klotho polypeptide to said mammal.

### Claim 4 (depends on 1)

The method of claim 1, wherein said method comprises administering exosomes comprising said nucleic acid to said mammal.

### Claim at position 5

5-9. (canceled)

### Claim 10

A method for increasing the ability of muscle progenitor cells to regenerate muscle cells within a mammal having a muscle impairment, wherein said method comprises:
(a) identifying said mammal as having said muscle impairment, and
(b) administering an α-Klotho polypeptide to said mammal.

### Claim 11

(canceled)

### Claim 12 (depends on 10)

The method of claim 10, wherein said mammal is a human.

### Claim 13 (depends on 10)

The method of claim 10, wherein said muscle impairment is sarcopenia.

### Claim at position 10

14-20. (canceled)

### Claim 21

A method for increasing the ability of muscle progenitor cells to regenerate muscle cells within a mammal, wherein said method comprises administering an exosome comprising an α-Klotho polypeptide or a nucleic acid encoding said α-Klotho polypeptide to said mammal.

### Claim 22 (depends on 21)

The method of claim 21, wherein said mammal is a human.

### Claim 23 (depends on 21)

The method of claim 21, wherein said mammal has sarcopenia.

### Claim 24 (depends on 21)

The method of claim 21, wherein said method comprises administering an exosome comprising said α-Klotho polypeptide to said mammal.

### Claim 25 (depends on 21)

The method of claim 21, wherein said method comprises administering an exosome comprising said nucleic acid to said mammal.

### Claim at position 16

26-49. (canceled)
